Search
Clinician Ordering Portal
On Demand Education
Integrating new technology into the management of non-dysplastic Barrett’s esophagus patients
Castle Biosciences hosted a case-based panel discussion at DDW 2023 highlighting how TissueCypher aids in the management of non-dysplastic Barrett’s esophagus patients.
Individualized Risk Prediction in Barrett’s Esophagus
Jul 2016
Medical Laboratory Observer
A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett’s Esophagus
Feb 2017
A Tissue Systems Pathology Assay for High-Risk Barrett’s Esophagus
May 2016
A Cost-Effectiveness Analysis of an Adenocarcinoma Risk Prediction Multi-Biomarker Assay for Patients with Barrett’s Esophagus
Oct 2019
Incorporating DecisionDx-Melanoma into Clinical Practice: Molecular Information for Personalized Management Decisions
Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients with Barrett’s Esophagus
Jun 2020
A risk prediction test identifies patients with non-dysplastic Barrett's esophagus who are at high risk for progression to high-grade dysplasia or cancer.
Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Non-Dysplastic Barrett’s Esophagus: A Spatial-Temporal Analysis
Oct 2020
Assessing additional spatial and temporal biopsies increased the predictive accuracy, allowing for identification of most future progressors.
Prediction of Progression in Barrett’s Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies
Feb 2022
Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.
Barrett’s Esophagus Panel: Predicting Progression in Barrett’s Esophagus Recent Advances Webinar
A panel discussion on the clinical challenges associated with predicting progression to esophageal adenocarcinoma in patients with Barrett’s esophagus.
Risk Stratification and Management of Dysplastic Barrett’s Esophagus
Jun 2022
Risk stratification is important in managing BE patients and biomarker assays such as TissueCypher® are “ready for Prime Time” in identifying patients at high risk for progression.
TissueCypher® Objectively Risk Stratifies Barrett’s Esophagus Patients with Low-Grade Dysplasia*
Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).
